Recombinant Protein Market worth $3.93 Billion by 2030, Registering a CAGR of 10.12%

New York, United States, June 03, 2022 (GLOBE NEWSWIRE) -- Recombinant protein is regarded as a manipulated form of the native protein, which is generated in a variety of ways in order to increase the production level of proteins, manufacturing useful commercial products, & modify gene sequences. The key factors that are spearheading the growth of the Global Recombinant Protein Market are an increase in R&D spending by pharmaceutical companies, the growing prevalence of chronic diseases, a surge in the number of regulatory approvals, and the continuous increase in the need for reducing viral infections. On the basis of Type, the Biologics segment held the largest market share of around 46.14%. On a regional basis, North America held the largest proportion of market share, with nearly 44.27% of the entire market. However, the Asia-Pacific (APAC) region witnessed the fastest growth rate with a robust CAGR throughout the duration period of 2020 to 2030.

To get a first-hand overview of the report, Request a Sample at 

https://www.strategicmarketresearch.com/request-sample/recombinant-protein-market

The report entailed by Strategic Market Research on the Recombinant Protein Market is ramified in terms of:

Product

· Growth Factors (Blood and Tissue) and chemokines

· Kinase proteins

· Human insulin

· Structural proteins

· Regulatory proteins

· Recombinant metabolic enzymes

· Adhesion molecules and receptors

· Membrane proteins

· Immune response proteins

· Others

Type

· Biologics

· Cell & gene therapy 

· Vaccines

End-User

• Biotechnology companies
• Contract research organizations
• Academic research institutes
• Pharmaceutical & biopharmaceutical companies
• Other end-users
  
  

Regions:

North America

• USA
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• Finland
• Switzerland
• France
• Russian Federation
• U.K
• Finland
• Turkey
• Netherlands 
• Belgium
• Spain
• Italy
• Rest of Europe
  
  

Asia Pacific

• China
• India
• Japan
• Indonesia
• South Korea
• Thailand
• Singapore
• Malaysia
• Philippines
• New Zealand
• Australia
• Rest of APAC

LAMEA

• Brazil
• Uruguay
• Saudi Arabia
• Argentina
• Rest of LAMEA
  
  

Make a Direct Purchase of the latest Blood Glucose Monitoring Devices Market Latest Report. Click the below link to initiate the purchase: 

https://www.strategicmarketresearch.com/buy-now/recombinant-protein-market

Pivotal factors augmenting the Market Growth:

• The continuous rise of chronic illnesses has increased the demand for recombinant protein therapies, thereby driving the market growth. The National Health Council has announced that chronic diseases affect nearly 133 million people in the United States each year, thereby representing over 40% of the total population of the country. In 2020, the number increased to around 157 million, with 81 million having multiple conditions. About 50% of all the adults in the USA have at least one chronic condition, & approximately 8 % of the children aged between (5 to 17) years are affected by chronic diseases.
  
  
• Apart from the surge in chronic diseases, the rise in funding of the worldwide government on R&D activities are also fuelling the market growth efficiently. Governments recognize R&D activities as a vital component of a country's growth. As per the Global R&D Funding Forecast, Global life science R&D spending rose up to 3.6 % (i.e. around USD 2.3 trillion) by 2019.
  
  
• Furthermore, a steep rise in the number of regulatory approvals for the treatment of uncommon conditions like haemophilia & other bleeding disorders are augmenting the overall market growth. 
  
  

In terms of Products, the ‘Growth Factors (Blood and Tissue) and chemokines’ segment dominated the market comprehensively.

In terms of Products, the market is split into Growth Factors (Blood and Tissue) and chemokines, Kinase proteins, Human insulin, Structural proteins, Regulatory proteins, Recombinant metabolic enzymes, Adhesion molecules and receptors, Membrane proteins, Immune response proteins, and others. The ‘Growth Factors (Blood and Tissue) and chemokines’ segment held the most significant proportion of the market at nearly 26.13% in 2020. The rise in application of growth factors & chemokines in many areas such as HIV, wound healing, immunology, neurobiology, etc., are driving the overall growth prospects of this segment. The Centres for Disease Control and Prevention have asserted that the United States roughly had 34,800 new HIV infections in 2020. More than 13% of the HIV-positive people in the USA are totally unaware of this condition & require diagnosis as soon as possible.

On the basis of Type, the ‘Biologics’ segment held the largest market share.

Based on Type, the market is ramified into Biologics, Cell & gene therapy, and Vaccines. The ‘Biologics’ segment held the maximum share of nearly 46.14% in 2020. The rising cases of target illnesses & increased government funding in research and development activities are fuelling the growth of this segment. Moreover, Biologics have been demonstrated in RCTs (randomized controlled trials) & are used regularly to reduce pain and swelling, skin and GI lesions, joint pain and stiffness (arthritis), etc. As per a research study, it was found that more than 350 million people worldwide are suffering from arthritis. In the United States, at least 1 out of 4 adults suffer from serious conditions of arthritis.

In terms of End-User, the ‘Pharmaceutical & Biopharmaceutical Companies’ segment held the maximum proportion of the market share.

For End-User, the market is bifurcated into Pharmaceutical & Biopharmaceutical companies, Biotechnology companies, Academic research institutes, Contract research organizations, and others. The ‘Pharmaceutical & biopharmaceutical companies’ held the maximum share in 2020. The continuous rise in demand for recombinant proteins for predictive, prognostic, or diagnostic identification, along with the need for accurate measurement of biomarkers in the field of drug research & development, are proliferating the growth of this segment.

North America led the market in all respects during the forecasted period.

North America led the market comprehensively in 2020, with a share of around 44.27% and was also regarded as the fastest-growing region. The continuous rising prevalence of chronic & infectious illnesses, increasing R&D investment, highly favourable conditions for government financing and the existence of some of the major market players are significantly driving the overall market growth of this region. A research survey showed that around 51.8% of the adults in the USA have at least 1 chronic condition, & 27.2% suffer from multiple chronic conditions. The rate of prevalence of chronic conditions is the highest among women. On the other hand, the adults aged 65 years or older & those living in rural areas also showed some prominent symptoms of chronic conditions.

Before initiating a purchase, make a Pre-order enquiry and get a detailed overview of the content of the report.

https://www.strategicmarketresearch.com/pre-order-enquiry/recombinant-protein-market

Pivotal market players in the Recombinant Protein Market:

• Thermo Fisher Scientific, Inc. (US)R&D Systems (US)
• Abcam plc (UK)
• Merck KGaA (Germany)
• Proteintech Group, Inc. (US)
• Janssen-Cilag Pty Ltd.
• Aviva Systems Biology
• Bio-Techne Corporation (US)
• Elpiscience 
• Elevian Inc
• Eli Lilly and co.
• GigaGen Inc.
• U Protein Express

Kindly go through and get access to our comprehensive coverage of myriad number of Healthcare reports published in the last three months: 
https://www.strategicmarketresearch.com/reports/healthcare

Recent Developments:

• On Jan 20th 2022, Elevian Inc announced that it is on the verge of developing a recombinant growth differentiation factor of 11 (rGDF11) to improve the recovery process after stroke. rGDF11 has been demonstrated to promote regeneration and functional recovery in preclinical models of both ischemic & haemorrhagic strokes. Additionally, rGDF11 has also been demonstrated in the preclinical models of multiple ageing-related conditions like cardiovascular, metabolic, neurodegenerative, & inflammatory diseases. However, the Phase I clinical trials are expected to start in early 2023.
  
  
• On Jan 13th 2022, Thermo Fisher successfully purchased recombinant protein maker PeproTech at around USD 1.85 billion. It proved to be an excellent strategic fit within the bioscience business sector of the organization & is expected to serve the various pharma and biotech customers by catering to their needs and adding new capabilities to the existing offerings for recombinant proteins.
  
  
• On Sep 30th 2021, GigaGen Inc successfully launched its new ProteoNic’s 2G UNicTM Technology Platform for the development & manufacturing of recombinant antibody drugs. This technology highly improves the recombinant protein production levels across a wide range of mammalian host cells, protein targets, and selection systems.
  
  

Related Reports:

Plasma Protein Therapeutics Market 

SMR’s ‘Global Plasma Protein Therapeutics Market Report with Insights & Forecast 2030’ elucidates a pellucid idea regarding the valuable analysis of the market insights like the restraining factors, driving factors, opportunities, etc. The overall valuation of the Global Plasma Protein Therapeutics market valued at USD 25.4 billion in 2020. It is predicted to be worth USD 50.4 billion by 2030, with a CAGR of 7.1 %. Key factors that are driving the market growth continuously are the increasing prevalence of autoimmune disorders & the rise in the geriatric population worldwide. The key organizations that are associated with the market are Octapharma USA Inc., Grifols, SA, Biotest AG, Takeda Pharmaceutical Company Ltd, Baxter, China Biologic Products Holdings Inc., etc.

Hormone Replacement Therapy Market 

SMR’s ‘Digital Hormone Replacement Therapy Market Report Insights & Forecast 2030’ highlights a concrete idea about the vital market insights like drivers, restraints, future opportunities, etc. In 2020, the Hormone Replacement Therapy Market summed up to USD 23.156 billion. It is projected to reach USD 39.631 billion by 2028, representing a CAGR of 7.83 %. The major factors expediting the market growth are the rise in prevalence of menopausal illness & increased awareness of post-menopausal difficulties. The key organizations associated with it are Abbott Laboratories, Bayer Ag.Eli Lily And Company, Pfizer Inc., Hisamitsu Pharmaceutical Co., Hoffmann-La Roche Ltd. (Genentech, Inc.), Inc. (Noven Pharmaceuticals, Inc.), Merck Kgaa, etc.

Negative Pressure Wound Therapy Market 

SMR’s ‘Negative Pressure Wound Therapy Market Report Insights & Forecast 2030’ inculcates a 360-degree idea regarding the key market insights such as restraining factors, opportunities, drivers, etc. The Negative Pressure Wound Therapy Market share valued at around USD 2.25 billion, and it is forecasted to reach USD 3.92 billion, with a 5.7% CAGR. The essential factors that are fuelling the market growth are the advent of technologically advanced NPWT Devices, the increasing number of chronic wounds, increased success rate of NPWT, etc. The key companies involved in this market are Smith & Nephew, ConvaTec Inc., Cardinal Health, Medela AG, Mölnlycke Health Care AB, Talley Group Ltd., etc.

Live Cell Imaging Market

SMR’s ‘Live Cell Imaging Market Report Insights & Forecast 2030’ explains a clear concept regarding the various market insights, like drivers, opportunities, restraints, etc. In 2020, the Global live-cell imaging Market size accounted for USD 1.8 billion, & the market is forecasted to expedite at a CAGR of 8.8% and reach around USD 4.18 billion by 2030. The pivotal factors that are proliferating the market growth are the rise in the adoption of high content screening in drug discovery, continuously increasing issues of chronic diseases, etc. Apart from that, the pivotal players associated with this market are Danaher Corporation, Carl Zeiss AG, Nikon Corporation, Olympus Corporation, PerkinElmer, Inc., G.E. Healthcare, Bruker Corporation, Thermo Fisher Scientific Inc., Sartorius AG, etc.

About Us:
Strategic Market Research facilitates the organizations globally in taking pivotal business decisions by furnishing the Syndicated and Customized Research Reports, which are highly precise in terms of market numbers. We believe that every firm, whether it is a startup which is in the Introduction stage of the Product Life cycle or an established one which is at the growth stage, requires market research services in order to streamline its key business blueprint. It may be related to Product Launch, Go to Market strategies, Competitive Analysis or new geographical penetration and expansion.

Contact Us:
Strategic Market Research LLP.
Sunil Kumar 
US: +1-8317045538
UK: +441256636046
India: +91-8260836500
Email: info@strategicmarketresearch.com
Web: https://www.strategicmarketresearch.com
Blog: https://www.strategicmarketresearch.com/blog
Press Release: https://www.strategicmarketresearch.com/press-releases

Connect Us:
LinkedIn: https://www.linkedin.com/company/strategic-market-research/
Twitter: https://twitter.com/smrstrategic
Facebook: https://www.facebook.com/StrategicMarketResearch
Instagram: https://www.instagram.com/strategicmarketresearchsmr/